Eledon Pharmaceuticals (ELDN) Enterprise Value (2013 - 2026)

Eledon Pharmaceuticals has reported Enterprise Value for 14 years, with the latest figure at -$216.0 million in Q1 2026.

• For the quarter ending Q1 2026, Enterprise Value fell 72.99% year-over-year to -$216.0 million; the trailing twelve-month figure through Mar 2026 stood at -$216.0 million (down 72.99% YoY), and the FY2025 full-year result was -$133.3 million, up 4.88% from the prior year.
• Enterprise Value for Q1 2026 stood at -$216.0 million, down from -$133.3 million in the prior quarter.
• The five-year high for Enterprise Value was -$9.2 million in Q2 2022, with the low at -$216.0 million in Q1 2026.
• Historically, Enterprise Value has averaged -$92.7 million across 5 years, with a median of -$83.6 million in 2024.
• Annual changes were most pronounced in 2022 — Enterprise Value jumped 90.22% — and 2023, when it slumped 1155.89%.
• Eledon Pharmaceuticals' Enterprise Value stood at -$56.4 million in 2022, then advanced by 9.41% to -$51.1 million in 2023, then tumbled by 174.31% to -$140.2 million in 2024, then grew by 4.88% to -$133.3 million in 2025, then sank by 62.02% to -$216.0 million in 2026.
• The last three Enterprise Value figures came in at -$216.0 million (Q1 2026), -$133.3 million (Q4 2025), and -$183.1 million (Q3 2025), per Business Quant data.